OSLO, Norway, Nov. 4, 2020 — Nel Hydrogen Electrolyser, a division of Nel ASA (Nel, OSE:NEL), has been selected as preferred supplier by Iberdrola for a 20 MW PEM solution for a green fertilizer project in Spain. Contract award is subject to mutual agreement on the final commercial terms. The hydrogen plant is scheduled to commence operations in 2021.
"We are very excited and honored that Iberdrola prefer to use a PEM electrolyser solution from Nel for this landmark green fertilizer project. It is a true testament to our PEM platform, which has been deployed all over the world for several decades. We continuously work to develop larger systems, and with this project our PEM platform will be designed into a 20 MW solution. We have over the course of the last year been working on both alkaline and PEM large-scale solutions, which serve different customer needs, and we look forward to provide our PEM solution for this project," says Filip Smeets, SVP Nel Hydrogen Electrolyser, Nel Hydrogen Fueling.
Iberdrola, one of the largest electricity utilities in the world, has together with a world-leading fertilizer manufacturer Fertiberia launched a project to establish the largest green hydrogen plant in Europe. Located in Puertollano, Spain it will feature a 100 MW photovoltaic plant, a battery installation with a storage capacity of 20 MWh, and a 20 MW electrolyser. The hydrogen produced in the project will primarily be used for green fertilizer production. The 20 MW electrolyser is scheduled to commence operations in 2021.
Contract award is subject to mutual agreement on the final agreement on terms and conditions, technical details, and board approval.
Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store, and distribute hydrogen from renewable energy. We serve industries, energy, and gas companies with leading hydrogen technology. Our roots date back to 1927, and since then, we have had a proud history of development and continuous improvement of hydrogen technologies. Today, our solutions cover the entire value chain: from hydrogen production technologies to hydrogen fueling stations, enabling industries to transition to green hydrogen, and providing fuel cell electric vehicles with the same fast fueling and long range as fossil-fueled vehicles – without the emissions.
OXFORD, England, Sept. 1, 2020 — GEN inCode UK Limited, the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the completion of a £3.0M institutional fundraise to internationally scale its products and technology.
GEN inCode specializes in genetic risk assessment and the prediction of cardiovascular disease. Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease, such as angina and myocardial infarction, often referred to as "heart attack". CVD also includes stroke, heart failure, hypertension, venous thromboembolism and other vascular heart diseases. CVD is the leading cause of death and disability worldwide accounting for one in every four deaths in the United States. By 2030, the total global cost of CVD is set to rise from approximately US $863 billion in 2010 to US $1,044 billion and is both a major health issue and global economic burden.
GEN inCode’s CE marked invitro-diagnostic products provide genetic information to enable patients, doctors and healthcare practitioners to assess and predict the onset of CVD. The Company’s products and ‘cloud-based’ reporting system help inform healthcare practitioners and patients of their CVD risk, enabling behavioural change alongside delivery of the most effective course of treatment.
GEN inCode has amassed significant investment in over 15 years’ worth of research data and the development of products and algorithms to assess disease risk and prevent the onset of CVD. In September 2018, the Company acquired the products, assets and know-how of the Ferrer inCode and the Gendiag.exe businesses, then part of The Ferrer Group, a large pharmaceutical and healthcare multinational company with headquarters in Barcelona, Spain. GEN inCode has now received institutional funding from Maven Capital Partners and Downing to expand its operations in Europe, the UK and U.S.
GEN inCode’s vision is to educate patients about their cardiovascular risk and to improve public health by using the predictive capability of its products with targeted therapies to determine lifestyle choice and improve patient outcomes.
Matthew Walls, Chairman and CEO, said:"We are delighted to complete the institutional round of funding and welcome Maven and Downing, our new institutional investors. The funding will prepare the Company for accelerated growth and international scale and supports our regulatory and clinical pathway into the U.S. market. We look forward to advising the market on our progress and further milestones in due course."
Jordi Puig, Co-founder and Group COO, said: "This marks another milestone in the development of our Company and prepares us to rapidly scale our products and technology across our European business."
GEN inCode is a UK-based company specializing in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide.
GEN inCode UK Limited operates business units in Europe and Latin America through GEN inCode S.L.U., and in the United States through GEN inCode U.S. Inc.
GEN inCode’s predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our CE marked invitro-diagnostic molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset.
NEUCHÂTEL, Switzerland, Aug. 31, 2020 — G-ray Switzerland, the medical imaging and industrial diagnosis start-up founded in 2014, has announced the appointment of Luis Pallares as Chief Executive Officer, as the company embarks on an accelerated growth drive and completes a successful funding round.
Mr Pallares is focused on leading the transformation of G-ray’s business development efforts following the company’s development of a disruptive and patented state of the art technology to bring safer, cheaper and better vision into imaging for medical and industrial diagnosis.
Mr Pallares joins G-ray with a wealth of entrepreneurial and start-up experience, having founded Spain’s first streaming service, Addhoc Streaming, Spanish-speaking health related content site Vivir Mejor, and Spain’s leading digital strategy firm, Nennisiwok.
Most recently Mr Pallares’ deep experience in technology development, artificial intelligence and digital advertising led him found Plyzer Technologies, a global leader of price comparison technology matched with business analytics and intelligence based on artificial intelligence.
The appointment coincides with the news that G-ray has also raised a further CHF 2.6 millions, enabling it close out its successful Series A funding round at CHF 28 million.
Luis Pallares, Chief Executive Officer of G-ray, said: "G-ray has already proven to be a positive disruptive force within the technology industry and I relish the opportunity to help deliver tangible progress by bringing improvements in imaging into medical and industrial diagnosis."
Mr Yves Claude Aubert, Chairman of G-ray Switzerland, said: "Our technology has already started to disrupt the multi-billion particle detection imaging markets, based on our proprietary and transformative unique detector architecture. As artificial intelligence impacts the traditional X ray detector market, Luis is the perfect choice to lead G-ray forward into a new phase of growth and to capture these opportunities.
About G-ray Switzerland
Founded in 2014 in Neuchâtel, G-ray Switzerland SA has filed a number of revolutionary patents in the fields of radiographic imaging and new semiconductor assembly techniques. The rapidly expanding company has developed core skills in monolithic detectors with integrated high-resolution CMOS circuits. These innovations cover a wide range of sectors, including automotive, aerospace and medicine. www.g-ray.ch
– Completes first phase in committed investment of US$ 150M (> INR 1000 Cr)
– Sri KT Rama Rao, Hon’ble Minister for Industry & Commerce and IT, Government of Telangana inaugurates the facility
HYDERABAD, India, Aug. 17, 2020 — Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the inauguration of its new Research and Technology (R&T) Centre in Hyderabad, India. SriK T Rama Rao, Hon’ble Minister for Industry & Commerce and IT, Government of Telangana formally inaugurated the facility in the presence of other dignitaries.
Sai Life Sciences New Research & Technology Centre
Speaking on the occasion, Sri KT Rama Rao said, "I’m very happy that the esteemed leadership of Sai Life sciences has considered Telangana for setting up their new R&D centre. Life Sciences is one of the key focus sectors for the Government of Telangana. Hyderabad serves more than 1000 global innovators in their vision to develop innovative and affordable medicines for the world. I sincerely congratulate the entire team of Sai Life Sciences, not only for the new Research & Technology Centre but, also for their work towards the development and manufacturing of new life saving medicines."
Built with an aspiration to achieve the best global benchmarks in lab infrastructure, the new R&T facility has several unique aspects such as intelligent & ergonomic lab design to enhance safety and productivity, advanced automation for seamless data capture during process development, lean & 5S approach to enhance productivity and collaborative workspaces for engendering innovation.
Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences said, "Our philosophy behind building this new facility was to go beyond what the norm is in India and to create what our global innovator partners expect in their inhouse capabilities." He further added, "We are an example of what is possible in Hyderabad’s rich life sciences ecosystem. Today, as we build world class R&D capabilities and invest in nurturing talent with deep domain expertise, I can unhesitatingly say, Hyderabad is truly a city where pharma dreams are made."
The new 83,000 sq.ft. (7700 sq.m.) facility houses state-of-the-art research capabilities and advanced technology platforms, augmenting the company’s capabilities in providing superior scientific solutions to its pharma and biotech innovator customers globally. It has 24 chemistry labs with 250 fume hoods, analytical labs, fully equipped technology suite and a dedicated process safety lab.
Sai Life Sciences began a process of organizational transformation in 2019 reinventing itself as a new generation global CDMO. Through this initiative, named Sai Nxt, the company is investing over US$ 150M (> INR 1000 Cr) to expand and upgrade its R&D and manufacturing facilities, induct top-notch global scientific and leadership talent, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.
About Sai Life Sciences Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines by 2025. It works with innovator pharma and biotech companies globally, accelerating the discovery, development and manufacture of complex small molecules. A pure-play CDMO, Sai Life Sciences has served a diverse set of NCE development programs, consistently delivering value based on its quality and responsiveness. Today, it works with 7 of the top 10 large pharma companies, as well as several small and mid-sized pharma & biotech companies. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com/
Inauguration of Sai Life Sciences’ New Research & Technology Centre. Seen in the picture from left to right – Krishna Kanumuri, CEO & MD Sai Life Sciences, Sri K T Rama Rao, Hon’ble Minister for IT, Industries, MA & UD and Jayesh Ranjan, Principal Secretary to Government Industries and Commerce
SEOUL, South Korea, July 27, 2020 — VUNO Inc., South Korean artificial intelligence (AI) developer and a member company of the Born2Global Centre, announced that VUNO Med®-Fundus AI™, its AI-based screening solution for the fundus, gained the honor of being the first-ever Innovative Medical Device in Korea by the Ministry of Food and Drug Safety (MFDS) in recognition of its high level of technological innovation. VUNO has proved its technological excellence in retinal fundus imaging analysis.
The MFDS was unanimously elected to be the first chair of Artificial Intelligence Medical Devices (AIMDs) at the International Medical Device Regulators Forum (IMDRF) held on June 25. All the credit goes to the agency’s continuous effort to set the path for the leading regulatory framework of AI-based medical devices by establishing guidelines for approval and review of AI-based medical devices in 2017 for the first time in the world.
With the MFDS taking at the helm, the Innovative Medical Devices are classified and designated among candidates that excel in safety and effectiveness compared to conventional medical apparatuses and treatments. The following is included in the evaluation criteria: technological intensity and pace of technological innovation (technological innovation); enhancement in safety and effectiveness compared to the existing medical devices (performance); and economic, social, and technological ripple effect (contribution to the public good and industrial value).
VUNO Med®-Fundus AI™ analyzes retinal fundus images to detect more than 12 lesions and classifies them for diagnosis. The 12 findings detected by the device are an all–encompassing set of medical information that is crucial to diagnosing a wide range of retinal diseases including diabetic retinopathy, macular degeneration and glaucoma.
VUNO Med®-Fundus AI™ ranked top in the Automatic Detection Challenge on Age-related Macular Degeneration at the International Symposium on Biomedical Imaging (ISBI) 2020, following the winning of the Diabetic Retinopathy – Segmentation and Grading Challenge at the same competition in 2018 and the Medical Image Computing and Computer Assisted Intervention (MICCAI) 2018 Retinal Fundus Glaucoma Challenge. In addition, a clinical research paper published in Ophthalmology, one of the most prestigious academic journals in the field, validated the solution’s remarkable detection performance.
VUNO Med®-Fundus AI™, was approved as a Class III medical device in April by the MFDS based on the solution’s proven effectiveness and performance through a series of clinical trials. Furthermore, in June, it gained the Class IIa CE marking according to the European Union (EU) framework, thus allowing VUNO Med®-Fundus AI™ to be commercially launched in 27 EU member states and others that recognize the European CE mark.
SHANGHAI and SAN DIEGO, July 9, 2020 — WuXi AppTec is pleased to announce that they are about to launch the second session of the webinar series “Collaborations That Transform,” highlighting the impact of partnerships in bringing effective therapies to patients. This complimentary webinar, to be broadcast worldwide on July 16, will convene leading physicians, drug developers, patients and advocates. These experts will discuss the latest advances in the development of transformative medicines for hemophilia, including gene therapy and next generation technologies.
As an enabler of the biotech and medical device industry, WuXi AppTec shares the conviction that we must work collaboratively to solve industry-wide problems and bring transformational medicines to people living with rare diseases. On July 16, the webinar will continue the dynamic discussions that began with WuXi AppTec’s inaugural rare disease webinar in May. It is complimentary and open to the public.
WuXi AppTec welcomes all to join the conversation.
10:35 – 11:00 Addressing the Unknowns in an Era of Transformations
A conversation with Glenn Pierce, VP Medical, World Federation of Hemophilia, Entrepreneur-in-Residence at Third Rock Ventures, and Chief Medical Officer at Ambys Medicines; moderated by Hui Cai, VP and Head of Content Division, WuXi AppTec
11:00 – 12:00 The Quest for Transformative Medicines
John Pasi, Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine and Dentistry, Queen Mary University of London
Richard Pezzillo, Executive Director, New England Hemophilia Association
Glenn Pierce, VP Medical, World Federation of Hemophilia
Rogerio Vivaldi, President & Chief Executive Officer, Sigilon Therapeutics
Guy Young, Director, Hemostasis and Thrombosis, Children’s Hospital Los Angeles; Professor of Pediatrics, University of Southern California Keck School of Medicine
Moderated by Richard Soll, Head of WuXi AppTec’s Boston office; Senior Advisor of Strategic Initiatives
Paige leveraged the world’s largest dataset in pathology to develop an unparalleled computation pathology offering
SANTA CLARA, California, July 8, 2020 — Based on its recent analysis of the North American AI-based digital pathology market, Frost & Sullivan recognizes Paige with the 2020 North American Enabling Technology Leadership Award for its disruptive product offering.
Paige
Paige has developed robust machine learning models for computational pathology for detecting cancer subtypes, thereby enhancing the diagnosis capability of pathologists worldwide. Paige’s AI-based technology was developed and tested on over 100,000 de-identified, digitized slide images from more than 16,000 cancer patients. The deep learning algorithms detected prostate cancer, skin cancer, and breast cancer with near-perfect accuracy.
“Paige’s AI algorithms validated against the world’s largest dataset in pathology makes it the most trustworthy best in class pathology diagnosis solution,” said Debarati Sengupta, Industry Analyst, Frost & Sullivan. “Paige’s technology eliminates the need to curate datasets, which is time-consuming and expensive. Paige’s AI based pathology offering enables pathologists to make a fast and accurate diagnosis of even the most complex and difficult to interpret slides.”
The Paige offering consists of general and organ-specific products that provide rapid diagnostic stratification, cancer detection, tumor segmentation, and prediction of treatment response, and overall survival. Its algorithms form a portfolio of AI-based digital diagnostics and biomarkers to help pathologists provide diagnoses. For security purposes, all datasets used to build the products were de-identified, and any protected health information or label text was removed.
Notably, Paige’s computational pathology offering received the Breakthrough Device designation by the US Food and Drug Administration (FDA) in 2019, making it the first such device for cancer diagnosis. Furthermore, it began commercializing in 2019 following its CE mark approval for Paige Prostate, which is a first-to-market prostate cancer detection solution, and a digital pathology viewer for the primary diagnosis of any digital slide. Paige’s AI-based solutions are vendor agnostic, which helps it serve a wider pool of customers.
In 2020, it formed a strategic partnership with Invicro LLC, a Konica Minolta company to provide its AI-based integrated pathology solutions to support Invicro’s drug discovery and development initiatives. “Paige continues to expand its footprint not just in commercial laboratories, but also in biopharmaceutical companies, positioning itself as a pioneer in AI-based digital pathology market” noted Sengupta.
Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of new products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Frost & Sullivan For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
About Paige Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make faster, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, minimize IT burden and costs while ensuring patient safety and data privacy. Our products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first and only company to receive FDA breakthrough designation for computational pathology products.
SINGAPORE, June 25, 2020 — Singapore-based biotech company TurtleTree Labs today announced the completion of a fresh round of funding from global investors. TurtleTree Labs is the world’s first-cell based biotechnology company creating real milk from mammalian cells, without the need for animals. As a platform, the company’s focus is on high value human breast milk followed by cow milk.
TurtleTree Labs Founders Max Rye and Fengru Lin
Over the past year TurtleTree Labs has attracted world class talent, currently boasting a team of more than 20 full-time scientists and engineers. With multiple cross-functional teams working in parallel, co-founder and CEO Fengru Lin says, “Our team is hungry, passionate and knows what it takes to accelerate to market. I’m so inspired when even the most junior scientists are sharing ideas of cutting costs or identifying better suppliers.”
With support from the Singaporean government, the startup has been privy to an array of resources that provided TurtleTree Labs with a tremendous financial boost, enabling it to continue working during the COVID-19 pandemic. Co-founder Max Rye, originally from the San Francisco Bay area explains, “Our teams are firing on all cylinders thanks to Enterprise Singapore and the support from our investors. We remain as focused as ever, and we aim to continue hitting milestones.”
“TurtleTree Labs’ goal of creating milk from animal cells provides a novel solution towards sustainable dairy production globally, and would also help to strengthen Singapore’s long-term food diversification efforts. We are encouraged that Singapore’s foodtech infrastructure has enabled homegrown startups like TurtleTree Labs to push technological boundaries and obtain quick access to capital. We will continue our efforts to develop a vibrant agri-food tech ecosystem in Singapore to encourage the creation of more innovative solutions,” said Ms Bernice Tay, Director, Food Manufacturing Division, Enterprise Singapore.
Investors taking part in the TurtleTree Labs seed round are Green Monday Ventures, KBW Ventures, CPT Capital, Artesian, and New Luna Ventures.
“Food tech innovation in Asia is way overdue. If the rapidly deteriorating climate change situation isn’t enough to convince the world, the pandemic surely hammers home the urgency that we need to overhaul the food system for the sake of public health, food safety, and food security. That explains why Green Monday Ventures is so excited to invest in and collaborate with TurtleTree Labs. We see immense possibilities in their biotech innovation platform, as well as enormous impact we can drive together,” says David Yeung, founder, Green Monday Group
“KBW Ventures has invested in the seed round building on our initial commitment during TurtleTree’s pre-seed raise. We see the founding team commitment and the potential of this company and its technology as a winning combination. Now more than ever, people are waking up to the benefits of food technology and the massive positive implications of innovations in cellular agriculture,” said Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures.
TurtleTree Labs raised its initial investment which was led by New York–Hong Kong based Lever VC in 2019, with investors from various geographies. “This fresh round of funding will enhance our scale up development, bringing us one step closer to commercialization,” said Max Rye.
TurtleTree Labs – TurtleTree Labs is the first biotech company in the world with the ability to create milk from all mammals. Using their proprietary cell-based methods, they will shape the future of not just how we get dairy milk but how humans will feed their infants. To maximise impact, the team will work with industry leaders to adopt their sustainable and safe methods to create milk. Their focus on impact will disrupt this multi-billion dollar industry while reducing the carbon footprint on this planet, while creating milk free of contaminants. Their innovation will provide millions access to safer, reliable and higher quality dairy products.
Green Monday Ventures – Green Monday Group has an overall mission to “Make Change Happen, Make Green Common” since its establishment in 2012. It is achieved by promoting plant-based eating and environmental protection through its multifaceted social venture model, in hopes of tackling climate change, global food in security and promoting public health. Green Monday Foundation, Green Monday Holdings and Green Monday Ventures are the three main branches of Green Monday Group. Green Monday Ventures is the impact investment arm aimed at accelerating the growth of mission-aligned entrepreneurs and startups globally.
KBW Ventures – KBW Ventures, founded by Chief Executive Officer HRH Prince Khaled bin Alwaleed bin Talal Al Saud, invests in companies with transformative technologies and business models and the potential for significant financial returns while also delivering positive social impact. The KBW Ventures portfolio spans the venture capital spectrum from earlier stage ventures, to more established companies looking to expand into the Middle East.
CPT Capital – CPT Capital is the venture arm of a leading private family office. As a long-standing dedicated investor in the alternative protein space, CPT Capital has unmatched experience and expertise investing in companies disrupting the food system.
Artesian – Artesian is a full-stack VC firm investing from seed stage through to exit. The Artesian portfolio comprises over 400 investments across Australia, China, South East Asia, South Asia and the Americas.
New Luna Ventures – New Luna Ventures is a leading impact venture capital advisor and investor in the food 2.0, agriculture, energy, community enrichment, and enabling software industries. We help entrepreneurs build sustainable ventures and connect disruptive ideas with investors and partners. Together, we provide actionable plans, enhanced communications, and expanded access to markets.
SHANGHAI, May 20, 2020 /PRNewswire/ — With the pandemic putting healthcare systems under strain worldwide, Electronic Health Record (EHR) systems are also shifting requirements for data security and sharing. As the leading public blockchain platform, VeChain furthers the collaboration with I-Dante to co-develop E-HCert App, which provides an archival solution for COVID-19 RT-PCR (real time-polymerase chain reaction) and antibodies tests (Rapid Test) records.
The success between VeChain and I-Dante previously on blockchain-enabled medical solution has led to the idea for the E-HCert App, which is now adopted by the Mediterranean Hospital of Cyprus. The new EHR system provides a secured method of on-chaining the COVID-19 related tests, giving the result of the health status of the individual, and allowing all concerning parties to access said health information at the discretion of the individual. With this set up, the individual can go about life as usual.
Compatible EHRs Should Compare Notes On The Pandemic
In the case of COVID-19, the testing results of citizens can be vital for public welfare and personal rights. Authorities worldwide are calling healthcare institutions to provide secure and legit access to health status information. Citizens themselves would also need trustworthy and reliable proof for their own health condition and full control over their privacy. However, current EHR systems are revealing serious deficiencies in terms of its interoperability, immutability, compliance, and the cost.
There is, therefore, an urgent need for the collection of trustworthy and standardized encrypted medical records that can be safely shared between multi parties. This is where blockchain technology comes in and becomes the de facto choice for such an implementation.
The Most Feasible Choice For EHR reform: The Public Blockchain
This public blockchain-based E-HCert App provides an archival solution for COVID-19 RT-PCR (real time-polymerase chain reaction) and antibodies tests (Rapid Test) records, which will be utilized to enhance the hospital’s COVID-19 management and response at the end of May 2020.
When a Cyprus citizen goes to the hospital and undergoes RT-PCR and antibodies tests, the testing records will be uploaded onto the VeChainThor Blockchain, and the immutably recorded results are then shown in the E-HCert Native App. As E-HCert fully complies with theGDPR, the App enables the owner to have complete control over their profiles, and use it to prove his or her health status when trying to return to work, take a flight abroad, and get authorized for other activities.
Compared with traditional technologies, blockchain provides better opportunities for companies to review their healthcare data systems, optimize the workflow design, while simultaneously enabling every patient to safely hold their records and share it immediately with any party in the world.
As the world’s leading public blockchain platform, VeChain intends to use its experience in the blockchain industry to empower more partners in the healthcare sector. By doing so, VeChain will play a central role in the acceleration of the digitalization of the healthcare industry.
About Mediterranean Hospital of Cyprus
The Mediterranean Hospital of Cyprus is a modern private health care institution, one of the largest in Cyprus, with a mission to provide to all the citizens and the visitors of the country safe and high-quality medical services 24/7. The founder of the Mediterranean Hospital of Cyprus, Dr. Andreas Panayiotou has set as a goal the development and the establishment of a reliable infirmary, with flexible operational mechanisms, in order to gain the trust and recognition for the quality of its services from everybody. Mediterranean Hospital of Cyprus is the first private hospital that joined Cyprus’ General HealthCare System (GHS).
Founded in December of 2019 by Etna Digital Growth (a consultancy- software house company in Italy) and CircleServus LTD (a consultancy company in Cyprus) in order to build digital healthcare solutions leveraging the power of the VeChainThor Blockchain.
Launched in 2015, VeChain connects blockchain technology to the real world by providing a comprehensive governance structure, a robust economic model, and IoT integration. VeChain is the pioneer of real-world applications using public blockchain technology, with international operations in Singapore, Luxembourg, Tokyo, Shanghai, Paris, Hong Kong, and San Francisco. Together with our strategic partners PwC and DNV GL, we have established cooperative relations with many leading enterprises in different industries, including Walmart China, BMW, BYDr, H&M, LVMH, D.I.G, ENN, AWS, PICC, ASI etc. Learn more about VeChain, please join the VeChain BootCamp.
The new multiplex cytokine and cytotoxicity assays as a part of the Opto Cell Therapy Development 1.0 workflow will help users of the Berkeley Lights’ platform develop cancer immunotherapies faster
EMERYVILLE, Calif., April 28, 2020 /PRNewswire/ — Today, Berkeley Lights, Inc., a leader in Digital Cell Biology, launched new capabilities to empower the Opto Cell Therapy Development 1.0 workflow. The workflow consists of a collection of software capabilities, reagents, and protocols to be run on the Beacon® and LightningTM systems. With the new capabilities researchers can now perform multiple functional assays on thousands of individual T cells in just days, allowing them to recover live cells for downstream genomic analysis. This ultimately enables Berkeley Lights’ customers to link T cell phenotype and function to genotype on individual cells, consolidating the T cell functional analytic process into one innovative platform.
T cell-based therapies have shown great promise for cancer treatment, but developing these therapies is challenging because the process of killing cancerous tumors by T cells relies on studying and screening multiple cell-to-cell interactions—a time-consuming and complex procedure. Current techniques to assess T cell function don’t allow scientists to collect all of the required data from the same cell. The new multiplex cytokine assay and the cytotoxicity assay, along with the recently launched TCRseq Well Plate Kit allow scientists to define and test the function of individual T cells. These applications enable simultaneous functional interrogation of thousands of individual T cells as they interact with antigen-presenting cells or tumors. Live, individual clones can be recovered for downstream expansion or genomic analysis. The Opto Cell Therapy Development 1.0 workflow enables CAR-T cell phenotypic and functional screening, and the discovery of T cell receptors (TCRs) associated with specific T cell behaviors.
“With the Opto Cell Therapy Development 1.0 workflow, users of Berkeley Lights’ platform can now tailor the development of cell therapies that mediate the rapid destruction of multiple tumor cells to the few T cells that really do all the work,” said John Proctor, Ph.D., Senior Vice President of Marketing at Berkeley Lights. “The cytotoxicity assay visualizes killing activity from single T cells, such as multiplexed and serial killing, followed by live cell recovery for genomic analysis. This new assay avoids common problems associated with traditional killing assays, which measure average target cell lysis at fixed time points, obscuring kinetic details and ignoring the heterogeneity present in T cell subsets.”
Berkeley Lights will continue to release more cell therapy related capabilities to the Berkeley Lights platform in the coming months. Email info@berkeleylights.com for more info.
About Berkeley Lights Here at Berkeley Lights, we think cells are awesome! Cells are capable of manufacturing cures for diseases, fibers for clothing, energy in the form of biofuels, and food proteins for nutrition. So the question is, if nature is capable of manufacturing the products we need in a scalable way, why aren’t we doing more of this? Well, the answer is that with the solutions available today, it is hard. It takes a long time to find the right cell for a specific job, costs lots of money, and if you have picked a suboptimal cell line, has a very low process yield. The Berkeley Lights Platform delivers and links deep phenotypic, functional, and genotypic information at the single cell level. This is a new way to capture and interpret the qualitative language of biology and translate it into single cell specific digital information, which we call Digital Cell Biology. Using our platform, customers have the complete solution to find the best cells by functionally screening and recovering individual cells for antibody discovery, cell line development, cell therapy development, and synthetic biology. Using our systems and solutions, scientists can find the best cells, the first time they look. For more information, visit www.berkeleylights.com.
Berkeley Lights’ Beacon and Lightning systems and Culture Station instrument are for research use only. Not for use in diagnostic procedures.
